|
[1]LIU JT.The role and significance of autoantibodies in the clinical diagnosis of autoimmune liver disease[J].Chin J Immunol, 2013, 29 (6) :669-672. (in Chinese) 刘金涛.自身抗体在临床自身免疫性肝病中的作用和诊断意义[J].中国免疫学杂志, 2013, 29 (6) :669-672.
|
|
[2] KIM KA, JEONG SH.The diagnosis and treatment of primary biliary cirrhosis[J].Korean J Hepatol, 2011, 17 (3) :173-179.
|
|
[3]DU HH, LI QM, ZHOU XZ, et al.Diagnostic value of a variety of auto antibodies detection in patients with primary biliary cirrhosis[J].Chin J liver Dis:Electron Vers, 2013, 5 (1) :19-23. (in Chinese) 杜慧慧, 李青敏, 周希禛, 等.多种自身抗体联合检测在原发性胆汁性肝硬化中的诊断价值[J].中国肝脏病杂志:电子版, 2013, 5 (1) :19-23.
|
|
[4]SHI J, WU C, LIN Y, et al.Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis:a meta-analysis of randomized controlled trials[J].Am J Gastroenterol, 2006, 101 (7) :1529-1538.
|
|
[5]ZHU J, SHI Y, ZHOU X, et al.Observation on therapeutic efficacy of ursodeoxycholic acid in Chinese patients with primary biliary cirrhosis:a 2-year follow-up study[J].Front Med, 2013, 7 (2) :255-263.
|
|
[6]DUAN WJ, YOU H.Therapy advances in primary biliary cirrhosis[J].J Clin Hepatol, 2011, 27 (6) :719-720. (in Chinese) 段维佳, 尤红.原发性胆汁性肝硬化的治疗进展[J].临床肝胆病杂志, 2011, 27 (6) :581.
|
|
[7]RAUTIAINEN H, KARKKAINEN P, KARVONEN AL, et al.Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis:a three-year randomized trial[J].Hepatology, 2005, 41 (4) :747-752.
|
|
[8]TRIVEDI PJ, HIRSCHFIELD GM.Treatment of autoimmune liver disease:current and future therapeutic options[J].Ther Adv Chronic Dis, 2013, 4 (3) :119-141.
|
|
[9]JOIN E.EASL Clinical Practice Guidelines:management of cholestatic liver diseases[J].J Hepatol, 2009, 51 (2) :237-267.
|
|
[10]KIM KA, JEONG SH.The diagnosis and treatment of primary biliary cirrhosis[J].Korean J Hepatol, 2011, 17 (3) :173-179.
|
|
[11]KUBO S, IWATA S, SAITO K, et al.Successful treatment of primary biliary cirrhosis with etanercept in a patient with rheumatoid arthritis[J].Joint Bone Spine, 2011, 78 (5) :535-536.
|
|
[12]CAMPANATI A, GANZETTI G, DI SARIO A, et al.The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis[J].J Gastroenterol, 2013, 48 (7) :839-846.
|
|
[13]EFE C.Drug induced autoimmune hepatitis and TNF-αblocking agents:Is there a real relationship?[J].Autoimmun Rev, 2013, 12 (3) :337-339.
|
|
[14]STOJAKOVIC T, CLAUDEL T, PUTZ-BANKUTI C, et al.Lowdose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment[J].Atherosclerosis, 2010, 209 (1) :178-183.
|
|
[15]LEVY C, PETER JA, NELSON DR, et al.Pilot study:fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid[J].Aliment Pharmacol Ther, 2011, 33 (2) :235-242.
|
|
[16]KANDA T, YOKOSUKA O, IMAZEKI F, et al.Bezafibrate treatment:a new medical approach for PBC patients?[J].J Gastroenterol, 2003, 38 (6) :573-578.
|
|
[17]IWASAKI S, OHIRA H, NISHIGUCHI S, et al.The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis:A prospective, multicenter study[J].Hepatol Res, 2008, 38 (6) :557-564.
|
|
[18]PINES A, FISMAN EZ.ACE Inhibition with moexipril:a review of potential effects beyond blood pressure control[J].Am J Cardiovasc Drugs, 2003, 3 (5) :351-360.
|
|
[19]CHARATCHAROENWITTHAYA P, TALWALKAR JA, ANGULO P, et al.Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid[J].Digest Dis Sci, 2010, 55 (2) :476-483.
|
|
[20]COMBES B, EMERSON S, FLYE N, et al.Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis[J].Hepatology, 2005, 42 (5) :1184-1193.
|
|
[21]GONG Y, CHRISTENSEN E, GLUUD C.Azathioprine for primary biliary cirrhosis[J].Cochrane Database Syst Rev, 2007, 18 (3) :CD006000.
|
|
[22]GONG Y, CHRISTENSEN E, GLUUD C.Cyclosporin A for primary biliary cirrhosis[J].Cochrane Database Syst Rev, 2007, 18 (3) :CD005526.
|
|
[23]ASKARI F, INNIS D, DICK RB, et al.Treatment of primary biliary cirrhosis with tetrathiomolybdate:results of a double-blind trial[J].Transl Res, 2010, 155 (3) :123-130.
|
|
[24]HOU G, ABRAMS G, DICK R, et al.Efficacy of tetrathiomolybdate in a mouse model of multiple sclerosis[J].Transl Res, 2008, 152 (5) :239-244.
|
|
[25]CORPECHOT C.Primary biliary cirrhosis and bile acids[J].Clin Res Hepatol Gastroenterol, 2012, 36 (1) :s13-s20.
|
|
[26]KOWDLEY K, JONES D, LUKETIC V, et al.An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in PBC[J].J Hepatol, 2011, 54:s13.
|
|
[27]ZHANG W, FEI Y, GAO J, et al.The role of CXCR3 in the induction of primary biliary cirrhosis[J].Clin Dev Immunol, 2011, 2011:564062.
|
|
[28]HINTERMANN E, BAYER M, PFEILSCHIFTER J, et al.CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation[J].J Autoimmun, 2010, 35 (4) :424-435.
|
|
[29]LLEO A, GERSHWIN M, MANTOVANI A, et al.Towards common denominators in primary biliary cirrhosis:the role of IL-12[J].J Hepatol, 2012, 56 (3) :731-733.
|
|
[30] HIRSCHFIELD G, LIU X, XU C, et al.Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants[J].N Engl J Med, 2009, 360 (24) :2544-2555.
|
|
[31]MELLS G, FLOYD J, MORLEY K, et al.Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis[J].Nat Genet, 2011, 43 (4) :329-332.
|
|
[32] MYERS RP, SWAIN MG, LEE SS, et al.B-Cell Depletion With Rituximab in Patients With Primary Biliary Cirrhosis Refractory to Ursodeoxycholic Acid[J].Am J Gastroenterol, 2013, 108 (6) :933-941.
|
|
[33]TSUDA M, MORITOKI Y, LIAN ZX, et al.Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid[J].Hepatology, 2012, 55 (2) :512-521.
|
DownLoad: